Home / Awards / Global Generics & Biosimilars Awards 2024
The winners have been announced!
Global Generics & Biosimilars Awards 2024
09 Oct 2024 - 18:00 - 23:30
Hotel NH Milano Fiera
GGB Awards 2024 poster announcement with date and location details. The event will be on October 9, 2024 at Hotel NH Milano Fiera.

Sponsored By

ABOUT THE AWARDS

Join us in celebrating the 11th anniversary of the Global Generics and Biosimilars Awards, a valued recognition of outstanding accomplishments and groundbreaking innovations in the global off-patent pharmaceutical landscape. Held during CPhI Worldwide week in Milan, these prestigious Awards serve as a distinctive platform for industry leaders to convene, engage in insightful discussions about future prospects and challenges, and applaud the exceptional contributions of companies and individuals fostering positive transformations.

Celebrated across 14 distinguished categories, including Biosimilar Initiative of the Year, Leader of the Year, and API Supplier of the Year, we will honor the trailblazers shaping the industry.

Entries for the Global Generics and Biosimilars Awards are open to all at no cost. The thorough judging process will take place throughout the summer, with the announcement of finalists scheduled for September. Witness the unveiling of the winners during the Awards ceremony on Wednesday, 9 October, 2024.

Key details

  • Ceremony: Wednesday, 9 October, 2024
  • Free to attend!
  • Hotel NH Milano Fiera

 

Entries for the 2024 Awards have now closed. If you are interested in learning more about the 2025 Awards, please contact [email protected].

THE GLOBAL GENERICS & BIOSIMILARS AWARDS CATEGORIES 2024
WHO COULD ENTER

Open to any company which has acquired another company that is active in generics and/or biosimilars, or has acquired a portfolio of generic and/or biosimilar products.


WINNER

Eurofarma Laboratórios

FINALISTS
  • Aurobindo Pharma
  • Eurofarma Laboratórios
  • Sandoz
WHO COULD ENTER

Open to any company supplying off-patent active pharmaceutical ingredients (APIs) or intermediates.


WINNER

Centrient Pharmaceuticals

FINALISTS
  • Centrient Pharmaceuticals
  • Natco Pharma
  • Surge Laboratories 
WHO COULD ENTER

Entries may relate to any biosimilar currently marketed, approved or in clinical development, sales and marketing initiatives, distribution agreements or other initiatives aimed at increasing biosimilar usage.


WINNER

Sandoz

FINALISTS
  • Biogen (Biosimilars Business Unit)
  • Boehringer Ingelheim
  • Samsung Bioepis
  • Sandoz
  • Stada
WHO COULD ENTER

Open to any generics and/or biosimilars alliance, joint venture, distribution agreement, licensing deal or similar that does not involve the acquisition of another company or a portfolio of products.


WINNER

Adalvo

FINALISTS
  • Accord Healthcare
  • Adalvo
  • Surge Laboratories
  • Unipharm
WHO COULD ENTER

This category allows industry firms and organizations to highlight outstanding campaigns used to successfully promote and highlight generics, biosimilars and value-added medicines across the world. This could include awareness campaigns, efforts to highlight key industry contributions to a wider audience, or initiatives that raise the profile of off-patent medicines for healthcare industry stakeholders.


WINNER
  • Celltrion
  • Teva Pharmaceuticals
FINALISTS
  • Accord Healthcare
  • Celltrion
  • Canadian Generic Pharmaceutical Association
  • Surge Laboratories
  • Teva Pharmaceuticals
WHO COULD ENTER

Open to any company that generates at least a third, or at least US $250 million, of its annual sales from generics or biosimilars.


WINNER

Sandoz

FINALISTS
  • Accord Healthcare
  • Aurobindo Pharma
  • Samsung Bioepis
  • Sandoz
  • Stada
WHO COULD ENTER

Open to any company that generates at least a third, or at least US$250 million, of its annual sales from generics and biosimilars. Qualification for a region is dependent on the headquarters (not tax domicile) of a company’s generics and/or biosimilars business.

  • Company of the Year — Americas | sponsored byCerba Research company logo.
    WINNER

    Dr.Reddy's – Americas

    FINALISTS
    • Amneal
    • Dr.Reddy's – Americas
    • Eurofarma Laboratórios

  • Company of the Year — Asia-Pacific
    WINNER

    Samsung Bioepis

    FINALISTS
    • Aurobindo Pharma
    • Biocon
    • Samsung Bioepis
    • Surge Laboratories - Nabiqasim Pharma Group

  • Company of the Year — EMEA
    WINNER

    Stada

    FINALISTS
    • Generis Farmacêutica, S.A.
    • Sandoz Region Europe
    • Stada
WHO COULD ENTER

Humanitarian charity International Health Partners (IHP) has partnered with Generics Bulletin to create this Award. Entries could include: company approach to CSR, implementation, engagement plans, raining & education programmes, compulsory licensing and humanitarian aid donations.


WINNER

Eurofarma Laboratórios

FINALISTS
  • Adalvo
  • Centrient Pharmaceuticals
  • Eurofarma Laboratórios
  • Hemofarm Foundation
  • Olpha (ex-Olainfarm)
WHO COULD ENTER

Awarded to recognize outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers. These could include logistics providers, contract-research organisations, contract-manufacturers, law firms and consultants.


WINNER

Accord Healthcare (partnership with Synthon)

FINALISTS
  • Accord Healthcare (partnership with Synthon)
  • Adalvo
  • Affygility Solutions
  • Lambda Therapeutic Research
  • Rephine
  • Surge Laboratories
WHO COULD ENTER

Open to any member of the senior management team of a firm within the generics or biosimilars industries. Judges will want to see how the entered leaders have best applied company values within the business environment – achieving measured and sustainable growth, driving improved performance, delivering shareholder value, implementing robust strategies, engaging staff, demonstrating market knowledge and true customer insight.


WINNER

Richard Saynor, CEO, Sandoz

FINALISTS
  • Paul Tredwell, Executive Vice President, Accord Healthcare EMENA
  • Anil Okay, founder and CEO, Adalvo
  • V Muralidharan (Murali), CEO, Aurobindo Pharma Europe
  • Judit Serra, Director of Innovation and Technology Development, Centrient
  • Richard Saynor, CEO, Sandoz
  • Peter Goldschmidt, CEO, Stada
WHO COULD ENTER

Awarded to identify excellence in the regulatory sphere. This could include innovative approaches to obtaining marketing authorisations, regulatory milestones for individual companies, or developments that represent a wider breakthrough for the global generics and/or biosimilars industries.


WINNER

Abyolo

FINALISTS
  • Abyolo
  • Biocon
  • Samsung Bioepis
  • Sandoz
  • Stada
WHO COULD ENTER

Entries in this category could include known molecules that are repurposed for new indications, reformulated in a way that adds value for patients, put together in innovative combinations, or which feature added-value packaging or delivery methods.


WINNER

Adalvo

FINALISTS
  • Accord Healthcare, The UK Medicines Repurposing programme
  • Accord Healthcare
  • Adalvo
  • PharmEvo
  • Surge Laboratories
See the 2024 photo gallery!
HEADLINE SPONSOR

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry. IQVIA creates intelligent connections to deliver powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries. Learn more at www.iqvia.com.

OUR 2024 SPONSORS
Adalvo
Adalvo is a leading B2B pharmaceutical company in Europe with over 140 global partners in 143+ countries. The company's goal is to improve patient care by providing high-quality products and services through a smart collaboration network. Adalvo's unique approach is tailored to each partner, helping them grow their business and achieve their objectives, whether that's increasing revenue or expanding into new markets. The company also prioritizes employee development and community growth while striving for excellence. Adalvo's commitment to excellence and making a difference ensures that it remains a key player in the competitive pharmaceutical industry.
Aurobindo
Aurobindo’s mission is to become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.

The company that started less than four decades ago as a single unit manufacturing Semi-Synthetic Penicillin (SSP) has now grown into a $ 3.5 billion global business with presence in over 150 countries and in all major therapeutic segments; API, FDF, Biocatalysts , Vaccines, Peptides and Biologicals.

With multiple facilities approved by leading regulatory agencies such as USFDA, EU GMP, UK MHRA, South Africa-MCC, Health Canada, WHO and Brazil ANVISA, Aurobindo makes use of in-house R&D for rapid filing of patents, Drug Master Files (DMFs), Abbreviated New Drug Applications (ANDAs) and formulation dossiers across the world. Aurobindo Pharma is among the largest filers of DMFs and ANDAs in India.
Cerba Research
Cerba Research offers world-class clinical research services, dedicated to supporting life science companies in the successful development of predictive and precision medicines for the future. Their commitment is centered around delivering the next generation of healthcare by transforming research and advancing health collectively. The organization strives to contribute to the betterment of society by enabling people to lead healthier lives through its cutting-edge research initiatives.
Pharmacloud
Since its foundation in 2009, Pharmacloud has steadily built up its reputation as a provider of specialist advice and consultancy to both the pharma industry and financial investors. We offer a number of services, with a particular focus on commercial due diligence on off-patent products. However, we also work with big pharma companies on generic defence strategies, as well as with emerging pharma companies seeking to assess the potential market for their value-added generic products or biosimilars.

The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.
OUR 2024 SUPPORTERS
AAM
The Association for Accessible Medicines improves access to safe, quality and effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.
BIOSIMILARS COUNCIL
The Biosimilars Council works to increase patient access to lifesaving, affordable biosimilar medicines. Leveraging our deep relationships on Capitol Hill, in federal agencies like FDA and CMS, and in the states, we strive to create a positive regulatory, reimbursement, political and policy environment to assure biosimilars thrive, providing billions in savings to patients and the health care system. Our members include biosimilar manufacturers and stakeholders working to promote biosimilar products in the U.S. market.

The Biosimilars Council is a division of the Association for Accessible Medicines, an organization dedicated to improving access to safe, quality, effective medicine. To learn more, visit www.accessiblemeds.org
IGBA
The International Generic and Biosimilar medicines Association (IGBA) strengthens cooperation between associations representing manufacturers of generic and biosimilar medicines from around the world. Adopting a patient centric approach, IGBA works to improve patients’ access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. For more details, regarding IGBA and its member associations, see the IGBA website at: www.igbamedicines.org
IHP
In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.
Want to sponsor an award
Judges
''
AURELIO ARIAS
Director, EMEA Thought Leadership
IQVIA
''
DUNCAN EMERTON
Executive Director, Customer Intelligence & Analytics,
Citeline
Headshot of Vivian Fritteli.
VIVIAN FRITTELI
Chief Executive Officer
Generic and Biosimilar Medicines of Southern Africa
''
JIM KEON
President
Canadian Generic Pharmaceutical Association
''
EWAN LIVESEY
Founder and Managing Director
Birnam Oak Consultancy
''
AXEL MULLER
Associate Partner
Fidelio Healthcare Partners
''
MARNIE PETERSON
Chief Executive Officer
Generic and Biosimilar Medicines Association
''
JULIE REED
Executive Director
The Biosimilars Forum
''
DEAN RUDGE
Senior Writer
Generics Bulletin
''
WARWICK SMITH
Director
Shuffling Wonder Ltd
''
JAMES VANE TEMPEST
Managing Director
Jefferies International
''
DAVID WALLACE
Executive Editor
Generics Bulletin
FRANCES CLOUD
Managing Director
Pharmacloud
AURELIO ARIAS
Director, EMEA Thought Leadership
 IQVIA
Aurelio’s predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on various topics relevant to the pharmaceutical industry. He is considered a subject matter expert in several areas and speaks at numerous conferences worldwide, presents at board-level meetings and engages in consulting projects.
DUNCAN EMERTON
Executive Director, Customer Intelligence & Analytics,
 Citeline
VIVIAN FRITTELI
Chief Executive Officer
 Generic and Biosimilar Medicines of Southern Africa
JIM KEON
President
  Canadian Generic Pharmaceutical Association
Jim Keon is President of the Canadian Generic Pharmaceutical Association (CGPA), and President of Biosimilars Canada organizations representing Canada’s generic and biosimilar pharmaceutical sectors.
EWAN LIVESEY
Founder and Managing Director
 Birnam Oak Consultancy
Ewan is corporate and business development leader and qualified lawyer with over 25 years’ experience in the pharmaceutical industry with roles ranging from General Counsel to Chief Business Officer for global pharmaceutical companies. He has worked for some of the leading generic companies including IVAX, Lupin, Glenmark, Apotex and most recently Zentiva where he led the acquisition of Alvogen’s CEE business (acquisition of the year 2020).
AXEL MULLER
Associate Partner
 Fidelio Healthcare Partners
Axel Müller - by education a pharmacist with a PhD in Pharmaceutical Technology - worked for over 25 years for STADA Arzneimittel AG in very different business areas like General Management, Operations, M&A, M&S and Communications. Finally, he was appointed as STADA Executive Board Member for Production and Development from 2010 to 2013.
MARNIE PETERSON
Chief Executive Officer
 Generic and Biosimilar Medicines Association
Marnie Peterson is Chief Executive Officer of the Australian Generic and Biosimilar Medicines Association (GBMA) and previously lead the organisation’s educational arm, GBMA Education, responsible for a 4-year educational grant focussed on biosimilar medicines.
JULIE REED
Executive Director
 The Biosimilars Forum
Juliana (Julie) Reed currently serves as the Executive Director of the Biosimilars Forum, leading strategy for the group’s strategic efforts to increase access to and adoption of biosimilars. Reed served as the Forum’s President for more than eight years and was one of its founders. As the Biosimilars Forum President, Reed oversaw advocacy and awareness campaigns to advance biosimilar access and adoption in the United States. She brings more than 30 years of experience in the healthcare sector to the Forum. Most recently, Reed was Vice President and Global Corporate Affairs Lead with Pfizer, specializing in immunology, inflammation and biosimilars portfolios. She also has experience in executive roles leading global corporate and government affairs for Hospira and Coherus BioSciences.
DEAN RUDGE
Senior Writer
  Generics Bulletin
WARWICK SMITH
Director
 Shuffling Wonder Ltd
Warwick Smith was Director and then Director General of the British Generic Manufacturers Association (BGMA) for 25 years until December 2020. During that time, he was responsible for the launch of the British Biosimilars Association (BBA) and the negotiation with the British Department of Health of the generic medicines pricing and supply agreements which gave the suppliers of unbranded medicines freedom of pricing in the UK. For much of that period, he was a member of the Board and Executive of Medicines for Europe. Prior to that, he worked for the UK Government as a policy adviser, international negotiator and ministerial aide, before leaving to become a public affairs adviser in which capacity he helped launch the BGMA with UK Government support.
JAMES VANE TEMPEST
Managing Director
  Jefferies International
DAVID WALLACE
Executive Editor
 Generics Bulletin
FRANCES CLOUD
Managing Director
 Pharmacloud
Next Steps
Sponsorship Opportunities
Sponsorship of the 11th Global Generics & Biosimilars awards provides exclusive opportunities, targeted branding, thought leadership and lead generation. Seize the opportunity to come together, to educate and engage with the companies who matter to you most.

PREVIOUS GLOBAL GENERICS & BIOSIMILARS AWARD CEREMONIES

Want to view previous Global Generics & Biosimilars Awards? Take a look back at our previous Awards and winners.
Global Generics & Biosimilars image poster
Clinical

Global Generics & Biosimilars Awards 2023

Hotel Porta Fira, Barcelona
Celebrate a decade of excellence at the Global Generics and Biosimilars Awards and honour the remarkable accomplishments in the development, authorization, and distribution of global off-patent pharmaceuticals.

 

Headline sponsor

Company logo of IQVIA
Abstract blue and green spiral.
Clinical

Global Generics and Biosimilars Awards 2022

Frankfurt Marriott Hotel
The Global Generics and Biosimilars Awards honor the remarkable accomplishments in the development, authorization, and distribution of global off-patent pharmaceuticals.

 

Headline sponsor

Company logo of IQVIA